021-51111890
购物车（）
sales@molnova.cn
Mocetinostat
CAS No. 726169-73-9
Mocetinostat ( MGCD0103;MGCD 0103;MGCD-0103 )
产品货号. M15781 CAS No. 726169-73-9
An isotype-selective small molecule HDAC inhibitor that selectively inhibits HDAC1 (IC50=0.15 uM).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥292 | 有现货 |
|
| 10MG | ￥421 | 有现货 |
|
| 25MG | ￥648 | 有现货 |
|
| 50MG | ￥810 | 有现货 |
|
| 100MG | ￥1280 | 有现货 |
|
| 200MG | ￥1661 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Mocetinostat
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述An isotype-selective small molecule HDAC inhibitor that selectively inhibits HDAC1 (IC50=0.15 uM).
-
产品描述An isotype-selective small molecule HDAC inhibitor that selectively inhibits HDAC1 (IC50=0.15 uM); also inhibits HDAC2/3/11; no effect on HDAC4/5/6/7/8; induces hyperacetylation of histones and caused cell cycle blockade in various human cancer cell lines; inhibits growth of human tumor xenografts in nude mice; orally bioactive.Blood Cancer Phase 2 Clinical
-
同义词MGCD0103;MGCD 0103;MGCD-0103
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC1;HDAC11;HDAC2;HDAC3;HDAC4
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number726169-73-9
-
分子量396.44
-
分子式C23H20N6O
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESNC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CN=CC=C2)C=C1
-
化学全称Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Fournel M, et al. Mol Cancer Ther. 2008 Apr;7(4):759-68.
2. Zhou N, et al. J Med Chem. 2008 Jul 24;51(14):4072-5.
3. Raeppel S, et al. Bioorg Med Chem Lett. 2009 Feb 1;19(3):644-9.
2. Zhou N, et al. J Med Chem. 2008 Jul 24;51(14):4072-5.
3. Raeppel S, et al. Bioorg Med Chem Lett. 2009 Feb 1;19(3):644-9.
产品手册
关联产品
-
Givinostat
Givinostat or gavinostat, aslo known as ITF2357, is a potent and orally active histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.
-
GSK-3117391
GSK-3117391 (CHR-5154) is a novel macrophage-targeted HDAC inhibitor.
-
RGFP 966
RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
